Compare · AARD vs NVO
AARD vs NVO
Side-by-side comparison of Aardvark Therapeutics Inc. (AARD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AARD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 2389.2x AARD ($80.3M).
- Over the past year, AARD is down 69.6% and NVO is down 45.4% - NVO leads by 24.2 points.
- NVO has hit the wire 8 times in the past 4 weeks while AARD has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 16 for AARD).
- Company
- Aardvark Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $3.61-2.70%
- $41.16-4.13%
- Market cap
- $80.3M
- $191.82B
- 1M return
- -35.54%
- -10.07%
- 1Y return
- -69.59%
- -45.43%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 0
- 8
- Recent ratings
- 16
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AARD
- Aardvark Therapeutics downgraded by Morgan Stanley with a new price target
- Aardvark Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
- SEC Form 10-Q filed by Aardvark Therapeutics Inc.
- Aardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
- SEC Form EFFECT filed by Aardvark Therapeutics Inc.
- SEC Form 424B5 filed by Aardvark Therapeutics Inc.
- SEC Form S-3 filed by Aardvark Therapeutics Inc.
- SEC Form 10-K filed by Aardvark Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care